TY - JOUR
T1 - Modulating bile acid pathways and TGR5 receptors for treating liver and GI diseases
AU - Malhi, Harmeet
AU - Camilleri, Michael
N1 - Publisher Copyright:
© 2017 Elsevier Ltd
PY - 2017/12
Y1 - 2017/12
N2 - Bile acids are central signals in enterohepatic communication and also integrate microbiota-derived signals into this signaling axis. Discovery of the tissue distribution and signaling pathways activated by the natural receptors for bile acids, farnesoid X receptor and G protein-coupled bile acid receptor 1 (GPBAR1) also known as TGR5, and bile acid transporters has led to the development of therapeutic agents that target these molecules. Obeticholic acid, a selective FXR agonist, and NGM282, a non-mitogenic FGF-19 analog, are two of the agents in this pipeline. Obeticholic acid has been approved by regulatory agencies for use in patients with primary biliary cholangitis.
AB - Bile acids are central signals in enterohepatic communication and also integrate microbiota-derived signals into this signaling axis. Discovery of the tissue distribution and signaling pathways activated by the natural receptors for bile acids, farnesoid X receptor and G protein-coupled bile acid receptor 1 (GPBAR1) also known as TGR5, and bile acid transporters has led to the development of therapeutic agents that target these molecules. Obeticholic acid, a selective FXR agonist, and NGM282, a non-mitogenic FGF-19 analog, are two of the agents in this pipeline. Obeticholic acid has been approved by regulatory agencies for use in patients with primary biliary cholangitis.
UR - http://www.scopus.com/inward/record.url?scp=85032676174&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85032676174&partnerID=8YFLogxK
U2 - 10.1016/j.coph.2017.09.008
DO - 10.1016/j.coph.2017.09.008
M3 - Review article
C2 - 29102744
AN - SCOPUS:85032676174
SN - 1471-4892
VL - 37
SP - 80
EP - 86
JO - Current Opinion in Pharmacology
JF - Current Opinion in Pharmacology
ER -